Citadel Advisors
PLRX icon

Citadel Advisors’s Pliant Therapeutics PLRX Stock Holding History

Citadel Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.4K Sell
36,800
-5,000
-12% -$6.31K ﹤0.01% 12432
2025
Q4 		$51K Buy
41,800
+27,300
+188% +$41K ﹤0.01% 12025
2025
Q3 		$21.5K Sell
14,500
-23,900
-62% -$36.5K ﹤0.01% 12479
2025
Q2 		$44.5K Buy
38,400
+400
+1% +$565 ﹤0.01% 11831
2025
Q1 		$51.3K Buy
38,000
+21,100
+125% +$128K ﹤0.01% 12288
2024
Q4 		$223K Sell
16,900
-1,900
-10% -$25.9K ﹤0.01% 10250
2024
Q3 		$211K Sell
18,800
-15,400
-45% -$193K ﹤0.01% 10040
2024
Q2 		$368K Buy
34,200
+7,700
+29% +$99.3K ﹤0.01% 8704
2024
Q1 		$395K Buy
26,500
+7,100
+37% +$117K ﹤0.01% 8886
2023
Q4 		$351K Sell
19,400
-29,100
-60% -$443K ﹤0.01% 8827
2023
Q3 		$841K Buy
48,500
+4,900
+11% +$85K ﹤0.01% 6946
2023
Q2 		$790K Sell
43,600
-8,700
-17% -$206K ﹤0.01% 6951
2023
Q1 		$1.39M Buy
52,300
+15,400
+42% +$438K ﹤0.01% 6061
2022
Q4 		$713K Sell
36,900
-31,300
-46% -$654K ﹤0.01% 7502
2022
Q3 		$1.43M Buy
68,200
+47,900
+236% +$916K ﹤0.01% 6252
2022
Q2 		$163K Buy
+20,300
New +$130K ﹤0.01% 10899

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors's PLRX Position: Q1 2026 in Review

Citadel Advisors increased its Pliant Therapeutics (PLRX) stake by 25% in Q1 2026, buying an estimated $812K and bringing the position to 3,226,599 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #4687.

Citadel Advisors first reported a position in PLRX in Q2 2020 and has held it in 24 quarters since. The position peaked at $48.1M in Q1 2021. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Citadel Advisors held 3,226,599 shares of Pliant Therapeutics worth $4.07M as of Q1 2026.
  • Citadel Advisors bought 643,267 Pliant Therapeutics shares in Q1 2026, an estimated $812K.
  • Pliant Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4687 holding.
  • Citadel Advisors first reported a position in Pliant Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Pliant Therapeutics position peaked at $48.1M in Q1 2021.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.